April 29, 2020

4D Molecular Therapeutics Announces Upcoming Oral and Poster Presentations at the 23rd Annual Meeting of the American Society of Gene and Cell Therapy

- Oral presentations to include data on 4D-310 Product Candidate for Fabry Disease and 4D-A101 Aerosol Vector for Cystic Fibrosis and other Lung Diseases - Additional poster presentations to include data on 4D-C102 IV Low Dose Vector for Lysosomal Storage ...

May 30, 2019

4D Molecular Therapeutics Announces Presentation of Preclinical Data at the 6th International Update on Fabry Disease and Provides Clinical Update

- Novel vector, 4D-C102, demonstrates superior performance compared to commonly used AAV1, AAV8, and AAV9 - - Fabry product candidate, 4D-310, is on track for anticipated clinical trial initiation in 2020 - Superior transduction of 4DMT’s novel vector, 4D-C102, ...

February 19, 2019

4D Molecular Therapeutics Expands Leadership Team with Appointments and Promotions of Key Executives

Company adds manufacturing and quality expertise and broad financial, operational and legal experience with the appointments of Fred Kamal, PhD as chief technical officer and head of regulatory and quality and of August Moretti as chief financial officerCompany announces ...